Log In

 

Company Name : Boehringer Ingelheim

Thursday, March 1, 2018 11:59PM IST (6:29PM GMT)

(BW)(BOEHRINGER-INGELHEIM)

Boehringer Ingelheim Starts New Campaign: ‘Why wait in IPF?’


Rare Disease Day draws attention to the importance of early diagnosis and treatment of IPF.; Even though international guidelines recommend to offer antifibrotic treatment to the majority of individuals with IPF, research in Europe shows that around 40% of patients with confirmed IPF do not receive antifibrotic treatment.1; Boehringer Ingelheim provides physicians with insights into progression of IPF as well as the benefits of early diagnosis and intervention.


Ingelheim, Germany

On Rare Disease Day, 28 February, Boehringer Ingelheim emphasises the question: ‘Why wait in IPF?´ while awareness activities are focussing on highlighting the benefits of early diagnosis and considering early treatment of idiopathic pulmonary fibrosis (IPF). IPF is a rare, debilitating and fatal lung disease which affects approximately 3 million people worldwide.2

 

Diagnosing IPF can be difficult because typically, patients with IPF present with nonspecific symptoms usually attributed to ageing, deconditioning or other comorbidities.2 The median time from first symptoms to diagnosis is around two years.3 Early and accurate diagnosis of IPF is important, as interventions such as antifibrotic therapies, supplemental oxygen treatment, cough management and pulmonary rehabilitation may help patients to better manage their condition.

 

In IPF a key concern is that many patients who are diagnosed with the disease remain untreated. In 2016, 290 respiratory physicians from five European countries participated in an online survey about IPF treatment in patients under their care. The survey showed that, of patients with a confirmed diagnosis, 40% did not receive treatment.1

 

IPF is unpredictable and damage is permanent.Without appropriate medical intervention the opportunity to slow disease progression is lost. “Slowing disease progression and preserving lung function by reducing decline should be the primary goal for all physicians when treating individuals with IPF. For this reason, initiation of treatment at diagnosis is vital”, commented Professor Toby Maher, Royal Brompton Hospital, UK.

 

While a cure for IPF has not been found yet, two approved antifibrotic drugs shown to slow disease progression in IPF are recommended for the majority of patients by international guidelines.4 At the time of diagnosis, IPF patients should feel empowered to take an active approach to managing their disease by learning all they can about it, and discussing with their treating physicians what treatment options and approaches are available.

 

New resources released for Rare Disease Day can be found at Boehringer-Ingelheim.com.

 

More information on IPF for physicians can be found at inIPF. Further information for patients can be found at Life with IPF.

 

~ ENDS ~

 

Please click on the link below for ‘Notes to Editors’ and ‘References’:

 

https://www.boehringer-ingelheim.com/press-release/IPFwhywait

 

Intended audiences:

 

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business.

 

 

 

 


Click here for Media Contact Details
CONTACTS :

Boehringer Ingelheim
Corporate Communications
Media + PR
Dr. Kristin Jakobs
Phone: +49 6132 – 77 144553
Fax: +49 6132 – 77 6601
Email: press@boehringeringelheim.com


More News from Boehringer Ingelheim

24/06/2018 6:20PM

Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center

New Biologicals Development Center in Biberach, Germany bundles biologics development, increases capacity and expands clinical supply network Increased development capacities reflect research pipeline growth and ...

24/05/2018 2:45PM

Spiolto® Respimat® enables greater physical activity in people living with Chronic Obstructive Pulmonary Disease

Data presented at American Thoracic Society meeting underpin the benefits of Spiolto® Respimat® for physical activity in COPD1,2 Study published in American Journal of Respiratory and Critical Care Medicine ...

22/05/2018 8:47PM

Efficacy and safety of OFEV® reinforced in new presentations at ATS 2018

New analysis of the INPULSIS® and TOMORROW trials suggests treatment with OFEV® (nintedanib) associated with reduced risk of death in patients with idiopathic pulmonary fibrosis Separate analysis of ...

Similar News

25/06/2018 11:23AM

टैरो वार्षिक रिपोर्ट फॉर्म 20-एफ में उपलब्ध है

टैरो फार्मास्यूटिकल इंडस्ट्रीज लिमिटेड (एनवाईएसई:टैरो, “टैरो”) ने एलान किया है कि 31 मार्च 2018 को समाप्त वित्त वर्ष के लिए सिक्यूरिटीज एंड एक्सचेंज कमीशन (“एसईसी”) में दाखिल उसकी ...

No Image

25/06/2018 11:08AM

Taro Annual Report on Form 20-F Available

Taro Pharmaceutical Industries Ltd. (NYSE:TARO, “Taro”) announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2018, filed with the Securities and Exchange Commission (the ...